Results 221 to 230 of about 13,388,827 (299)

Pharmacokinetic and Pharmacodynamic Drug‐Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single‐Center, Single‐Arm, Phase I Study in China

Clinical Pharmacology in Drug Development, Volume 15, Issue 10, October 2026.
Abstract This single‐center, single‐arm, Phase I study evaluated drug–drug interactions (DDIs) between cofrogliptin and metformin in healthy Chinese subjects. Twenty‐two subjects sequentially received metformin monotherapy (Days 1–4), cofrogliptin monotherapy (Days 6–34), and combination therapy (Days 38–47).
Cheng Cui, Na Liu, Chang Chu, Shu Niu, Yang Huang, Fangqiong Li, Yaming Li, Haiyan Li, Dongyang Liu   +8 more
wiley   +1 more source

Glycemic control of once-weekly and other administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: a real-world retrospective cohort study. [PDF]

Diabetol Int
Koto R, Yoshida S, Nakajima A, Miwa T, Nishimura R.   +4 more
europepmc   +1 more source

Bioactive peptides in cancer and inflammation: Mechanisms, model systems and clinical translation

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Bioactive peptides (BAPs) derived from host, marine, insect, plant and synthetic sources share cationic, amphipathic structures adopting α‐helical, β‐sheet or cyclic conformations. These features underlie anti‐cancer effects, including membrane disruption, apoptosis and cell‐cycle arrest, anti‐metastatic activity, reduced invasion and migration, and ...
Najwa Doha, Richa Gill, Sergio Crovella, Haissam Abou‐Saleh, Sahar Isa Da'as   +4 more
wiley   +1 more source

Harnessing Terminalia arjuna in Next Generation Phytomedicine: Cutting Edge Nutraceutical Trends Shaping Food and Health

Food Science &Nutrition, Volume 14, Issue 10, October 2026.
This graphical abstract illustrates the complete translational pipeline of Terminalia arjuna in modern phytomedicine and functional food development. It is rich in key bioactive compounds like arjunolic acid, arjungenin, flavonoids, and tannins which serve as the foundation for the plant's versatile medicinal uses and offers broad therapeutic benefits ...
Ishani Banerjee, Fahika Nazeerulla, Manash Kumar Paul, Sujit Kumar Bhutia, Deblina Basu, Subhadip Mukhopadhyay   +5 more
wiley   +1 more source

PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes. [PDF]

Diabetes Metab Syndr Obes
Penaforte-Saboia JG, Couri CEB, Albuquerque NV, Linard LLP, Araújo DAC, de Oliveira SKP, Gomes TFP, Pinheiro MM, Castelo MHCG, Fernandes VO, Montenegro Júnior RM.   +10 more
europepmc   +1 more source

Elevated endogenous glucagon‐like peptide‐1 as a novel Alzheimer's disease biomarker associated with neuroinflammation and Aβ pathology

General Psychiatry, Volume 39, Issue 5, October 2026.
ABSTRACT Background Alzheimer's disease (AD), a neurodegenerative disorder, is pathologically defined by the accumulation of amyloid‐β (Aβ) plaques, hyperphosphorylated tau tangles and sustained neuroinflammation. Glucagon‐like peptide‐1 (GLP‐1), originally characterised as an incretin hormone, is also expressed endogenously in the brain.
Jianping Li, Chenhui Ji, Jintao Wang, Jinwen Xiao, Haixia Li, Xinyi Xie, Nan Zhi, Yaying Song, Wenwei Cao, Liling Wang, Jieli Geng, Rujing Ren, Gang Wang   +12 more
wiley   +1 more source

The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial. [PDF]

Diabetologia
Elbarbary NS, Ismail EA, El-Hamamsy MH, Ibrahim MZ, Elkholy AA.   +4 more
europepmc   +1 more source

DPP-4 Inhibitors as Antidiabetic Agents

Journal of Analytical & Bioanalytical Techniques, 2010
openaire   +1 more source

Assessing Extracellular Vesicle Proteins as Predictive Biomarkers for Developing Type 1 Diabetes

PROTEOMICS, Volume 26, Issue 10, Page 24-30, October 2026.
ABSTRACT Plasma extracellular vesicles (EVs) are considered excellent sources for biomarker discovery since they carry signatures of their cellular origin and disease processes. In this paper, we evaluate the potential of plasma EV proteomics analysis for identifying predictive biomarkers of developing type 1 diabetes (T1D), which results from ...
Panshak P. Dakup, Lisa M. Bramer, Athena Schepmoes, Ivo Diaz Ludovico, Javier Flores, Raghavendra G. Mirmira, Bobbie‐Jo M. Webb‐Robertson, Thomas O. Metz, Emily K. Sims, Ernesto S. Nakayasu   +9 more
wiley   +1 more source

Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who ...
Francesco Martines, Pietro Salvago, Francesca Vaccaro, Davide Vaccaro, Ginevra Malta, Fabiana Plescia, Stella Cascioferro, Gianluca Lavanco, Fulvio Plescia   +8 more
wiley   +1 more source